KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases: 2019-2025

Historic Operating Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $767,000.

  • Esperion Therapeutics' Operating Leases fell 76.75% to $767,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $767,000, marking a year-over-year decrease of 76.75%. This contributed to the annual value of $2.6 million for FY2024, which is 14.90% down from last year.
  • Per Esperion Therapeutics' latest filing, its Operating Leases stood at $767,000 for Q3 2025, which was down 41.54% from $1.3 million recorded in Q2 2025.
  • Esperion Therapeutics' Operating Leases' 5-year high stood at $4.4 million during Q1 2024, with a 5-year trough of $47,000 in Q3 2022.
  • Moreover, its 3-year median value for Operating Leases was $2.0 million (2023), whereas its average is $2.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 96.42% in 2022, then soared by 4,259.57% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Operating Leases (Quarterly) stood at $524,000 in 2021, then climbed by 26.91% to $665,000 in 2022, then soared by 354.14% to $3.0 million in 2023, then decreased by 14.90% to $2.6 million in 2024, then crashed by 76.75% to $767,000 in 2025.
  • Its Operating Leases stands at $767,000 for Q3 2025, versus $1.3 million for Q2 2025 and $2.0 million for Q1 2025.